Clinical trials: Dyskinesia
Huntington Disease
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B
This study is a phase 1, double-blind, placebo-controlled, multiple ascending dose study to determine the safety, tolerability, and pharmacokinetics of SAGE-718 oral solution in healthy adults (Part A) with an open-label cohort…
- Trial name
- NCT03787758
- Testing
- SAGE-718
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Chronic Cholecystitis, Biliary Dyskinesia
Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers
This open-label study will evaluate the effect of food on the bioavailability of a single dose of 4-MUST, tablets, 128 mg. Additionally, the study will assess the pharmacokinetics, safety, and tolerability of 4-MUST, tablets, 128…
- Trial name
- NCT07594977
- Testing
- 4-MUST
- Where
- Russia
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Huntington Disease
An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196
The primary objective of this study is to provide biological samples from patients with Huntington's disease to allow characterisation of the pharmacological mechanism of action of SEN0014196.
- Trial name
- PADDINGTON (NCT01485952)
- Testing
- SEN0014196 (Low Dose), SEN0014196 (High Dose)
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Siena Biotech S.p.A.
Parkinson's Disease (PD)
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).
- Trial name
- DYSCOVER (NCT02799381)
- Testing
- Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump
- Where
- 28 sites in United States, Finland and 5 more
- Volunteers
- 63 people
- Sponsor
- AbbVie
Parkinson's Disease
A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa
The purpose of this clinical trial is to determine the maximum tolerated dose of Fipamezole in adult patients with Parkinson's disease who are receiving levodopa.
- Trial name
- Fipamezole (NCT01140841)
- Testing
- Fipamezole ODT
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bausch Health Americas, Inc.
Parkinsons Disease
First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
This study is researching an experimental drug called ALN-SNCA (called "study drug"). The study is focused on people with early Parkinson's disease, a disorder of the nervous system that affects movement.
- Trial name
- NCT07216066
- Testing
- ALN-SNCA
- Where
- 3 sites in Canada, Netherlands
- Volunteers
- 46 people
- Sponsor
- Regeneron Pharmaceuticals
Parkinson Disease, Dyskinesia, Drug-Induced
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
The purpose of this study is to generate long-term safety, tolerability and efficacy data for AFQ056 in patients who have participated in and completed any AFQ056 phase II study in PD-LID (Parkinson's disease, L-dopa induced…
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
- Trial name
- NCT01173731
- Testing
- AFQ056
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Machado-Joseph Disease / Spinocerebellar Ataxia 3
Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease
This is an exploratory, randomized, parallel-group, dose escalation and dose-controlled study without a placebo arm. Eligible patients will be randomized in a 1:1 ratio (double-blind) to receive Cabaletta in 2 doses, once weekly…
- Trial name
- NCT02147886
- Testing
- Cabaletta for IV infusion once weekly during 24 weeks
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Bioblast Pharma Ltd.
Huntington Disease
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
The purpose of this study is to determine if Dimebon is safe and effective for the treatment of cognitive impairment in Huntington disease.
- Trial name
- HORIZON (NCT00920946)
- Testing
- Dimebon
- Where
- 37 sites in United States, Australia and 5 more
- Volunteers
- 403 people
- Sponsor
- Medivation, Inc.
Dyskinesia, Medication-induced
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia
- Trial name
- NCT00175955
- Testing
- Levetiracetam
- Where
- 7 sites in Belgium, Bulgaria
- Volunteers
- 70 people
- Sponsor
- UCB Pharma
Agitation in Patients With Dementia of the Alzheimer's Type
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) was to be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National…
- Trial name
- NCT02442765
- Testing
- AVP-786
- Where
- 126 sites in United States, Estonia and 4 more
- Volunteers
- 387 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Essential Tremor, Parkinson Disease
The Essential Tremor (ET) and Parkinson Disease (PD) Tremor Acute Stimulation Study
The current study is designed to test the hypothesis that targeted electrical stimulation will result in upper limb tremor reduction in ET and PD patients.
- Trial name
- NCT01940406
- Testing
- Stimulation procedure
- Where
- Israel
- Sponsor
- BlueWind Medical
Parkinson's Disease
Kinesia 360 Parkinson's Monitoring Study
Kinesia 360 is an ambulatory symptom monitoring device for Parkinson's Disease (PD). The aim of this study is to investigate the impact, validation, and usability of the Kinesia 360 system.
- Trial name
- NCT02657655
- Testing
- Kinesia 360
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Cervical Dystonia
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
Phase 3, open-label, multi-center trial to evaluate the long-term safety, efficacy, and immunogenicity of up to four continuous treatment cycles of daxibotulinumtoxinA (DAXI) for injection.
- Trial name
- ASPEN-OLS (NCT03617367)
- Testing
- daxibotulinumtoxinA for injection
- Where
- 65 sites in United States, Austria and 7 more
- Volunteers
- 357 people
- Sponsor
- Revance Therapeutics, Inc.
Cervical Dystonia
DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia
The purpose of the protocol is to determine typical patient response to Dysport in the treatment of adult cervical dystonia (CD).
- Trial name
- ANCHOR-CD (NCT01314365)
- Where
- 45 sites in United States
- Volunteers
- 350 people
- Sponsor
- Ipsen
Huntington Disease
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia.
- Trial name
- OPEN-HART (NCT01306929)
- Testing
- pridopidine
- Volunteers
- 134 people
- Sponsor
- Prilenia
Movement, Involuntary
NIBP (Non-invasive Blood Pressure) Algorithm Enhancements (Characterize the Robustness of Motion Artifact Suppression)
The study intervention consists of a non-invasive blood pressure (NIBP) measurement device and cuff (FDA-cleared Philips IntelliVue X3 Rev.
- Trial name
- NCT05185037
- Testing
- Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Huntington Disease
Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.
Cellavita-HD is a stem-cell therapy for Huntington's Disease. Open label, single treatment, extension study for long-term safety and efficacy evaluation of Cellavita-HD intravenous administration in Huntington's disease patients…
- Trial name
- ADORE-EXT (NCT04219241)
- Testing
- Cellavita-HD
- Where
- Brazil
- Volunteers
- 35 people
- Sponsor
- Azidus Brasil
Parkinson's Disease, Tremor
A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease
This is a Phase 2, multicenter, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks, a 4 week randomized double-blind, dose-titration treatment period, followed by a 1 week…
- Trial name
- NCT03436953
- Testing
- CX-8998
- Sponsor
- Jazz Pharmaceuticals
Huntington's Disease
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease.
- Trial name
- NCT02197130
- Testing
- PF-02545920
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 272 people
- Sponsor
- Pfizer